口服阿维A联合局部曲安奈德对比单用曲安奈德治疗症状性口腔扁平苔藓的随机临床试验
该单中心、安慰剂对照、研究者和患者双盲随机临床试验纳入64例症状性口腔扁平苔藓患者,比较口服阿维A(25-35 mg/d)联合0.1%曲安奈德与单用曲安奈德治疗28周及随访至36周的疗效。结果显示联合治疗组达到ODSS-75(ODSS较基线下降75%)的患者比例显著高于安慰剂组(28周:88% vs 47%;36周:84% vs 41%),且随访8周内复发率低。结论提示口服阿维A联合曲安奈德优于单用曲安奈德。
要点
- 口服阿维A联合曲安奈德可显著提高症状性OLP的ODSS-75应答率。
- 联合治疗在28周和36周均优于单药,组间差异约41-43个百分点。
- 治疗后8周随访复发率低,联合组与单药组分别为3%和6%。
核心结论
- 口服阿维A联合局部曲安奈德治疗症状性口腔扁平苔藓比单用曲安奈德更有效。
研究设计与样本
- 共纳入64例18岁及以上症状性口腔扁平苔藓患者,连续抽样招募。
- 治疗组接受口服阿维A(25-35 mg/d)联合0.1%曲安奈德,安慰剂组接受曲安奈德联合安慰剂,治疗28周,随后8周无治疗随访,总研究时长36周。
主要发现
- 意向性分析中,28周末治疗组28例(88%)达到ODSS-75,安慰剂组15例(47%),组间差异41个百分点(95%CI 20-61),P < .001,Cramér V = 0.47。
- 36周末治疗组27例(84%)达到ODSS-75,安慰剂组13例(41%),组间差异43个百分点(95%CI 23-67),P < .001,Cramér V = 0.47。
- 8周治疗后随访期间复发率低:治疗组1例(3%),安慰剂组2例(6%),组间差异3个百分点(95%CI -13至7),P > .99,Cramér V = 0.07。
关键数值与推荐
- 主要结局为28周和36周时达到ODSS-75(ODSS较基线下降75%)的患者数。
- 疾病严重度和治疗反应采用口腔疾病严重度评分(ODSS)、口腔健康影响概况14(OHIP-14)和视觉模拟量表(VAS)评估。
临床怎么用
- 对于症状性口腔扁平苔藓,可考虑口服阿维A(25-35 mg/d)联合局部曲安奈德以提升治疗应答。
- 联合治疗在28周和36周均显示更优的ODSS-75应答,且随访8周复发率低。
局限性
- 单中心研究,样本量64例,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Symptomatic oral lichen planus (OLP) can be challenging to treat. OBJECTIVE: To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP. DESIGN, SETTING, AND PARTICIPANTS: This monocentric, investigator-initiated, placebo-controlled, investigator- and patient-blinded randomized clinical trial was conducted from December 2018 to June 2020 at the Postgraduate Institute of Medical Education and Research, a tertiary referral center in Chandigarh, India. Sixty-four patients 18 years or older with symptomatic OLP were recruited by consecutive sampling. Data were analyzed from July to December 2020. INTERVENTION: The patients were randomized to receive either a combination of oral acitretin (25-35 mg/d) and TAC (treatment group) or TAC in combination with placebo (placebo group) for 28 weeks, with an additional 8 weeks of treatment-free follow-up after the end of treatment (36 weeks of total study duration). MAIN OUTCOMES AND MEASURES: The disease severity and treatment response were assessed using Oral Disease Severity Score (ODSS), Oral Health Impact Profile 14 (OHIP-14), and visual analog scale (VAS). The primary aim was to assess the number of patients achieving ODSS-75 (75% reduction in ODSS compared with baseline) in both groups at 28 weeks and at the end of 36 weeks. RESULTS: Among 64 patients, 31 in the treatment group and 30 in the placebo group completed the study (mean [SD] age, 50.6 [15.2] years vs 49.2 [14.4] years; male-female ratio, 13:19 vs 16:16). Baseline ODSS, visual analog scale, and Oral Health Impact Profile 14 scores were comparable in both groups. In the intention-to-treat analysis, there was a statistically significant higher number of patients achieving 75% or higher reduction in ODSS in the treatment group compared with the placebo group at the end of 28 weeks (28 [88%] vs 15 [47%], a 41 [95% CI, 20-61] percentage point difference between groups; P < .001; Cramér V = 0.47) and 36 weeks (27 [84%] vs 13 [41%], a 43 [95% CI, 23-67] percentage point difference between groups; P < .001; Cramér V = 0.47). Relapses during the posttreatment follow-up of 8 weeks were low among patients in both treatment and placebo groups (1 [3%] vs 2 [6%], a 3 [95% CI, -13 to 7] percentage point difference between groups; P > .99; Cramér V = 0.07). CONCLUSION AND RELEVANCE: In this randomized clinical trial, the combination of oral acitretin and TAC was more effective than TAC monotherapy in patients with symptomatic OLP. TRIAL REGISTRATION: Clinical Trial Registry of India Identifier: CTRI/2018/11/016448.
引用
- Vinay K, Kumar S, Dev A, et al. Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus: A Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 38055232. doi:10.1001/jamadermatol.2023.4889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。